Trial Profile
Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 24 Aug 2020
Price :
$35
*
At a glance
- Drugs 64Cu-MeCOSar-Octreotate (Primary) ; 67Cu-MeCOSar-Octreotate-Clarity-Pharmaceuticals (Primary)
- Indications Meningioma
- Focus Adverse reactions
- Sponsors Clarity Pharmaceuticals
- 28 Jan 2020 Status changed from active, no longer recruiting to discontinued.
- 16 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 25 Sep 2019 Planned End Date changed from 24 Jul 2020 to 25 Mar 2021.